Trial Profile
Efficacy of IOP reduction and safety of Mikeluna combination ophthalmic solution switched from Xalatan 0.005% and Mikelan LA 1%,2% ophthalmic solution.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Feb 2020
Price :
$35
*
At a glance
- Drugs Carteolol/latanoprost (Primary) ; Latanoprost
- Indications Glaucoma; Ocular hypertension
- Focus Adverse reactions; Therapeutic Use
- 01 Dec 2018 Status changed from recruiting to completed.
- 22 Feb 2017 New trial record